ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
April 25, 2018 16:18 ET
|
ARMO BioSciences
REDWOOD CITY, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin (AM0010), a...
ARMO BioSciences to Participate in Panel on Cytokines at 8th Annual Cancer Immunotherapy Conference
April 03, 2018 08:00 ET
|
ARMO BioSciences
REDWOOD CITY, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced that Martin Oft, M.D., Senior Vice President,...
ARMO BioSciences Reports FY 2017 Financial Results
April 02, 2018 08:00 ET
|
ARMO BioSciences
First Patient Enrolled in CYPRESS 1 Trial in Non-Small Cell Lung Cancer REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology...
ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer
March 29, 2018 08:00 ET
|
ARMO BioSciences
REDWOOD CITY, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced enrollment of its first patient in CYPRESS 2, a...
ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study
March 26, 2018 08:00 ET
|
ARMO BioSciences
Data Monitoring Committee Recommends Study Proceed Without Modification REDWOOD CITY, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology...